Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents
Interstitial lung diseases (ILDs) encompass a heterogeneous group of over 200 disorders that require individualized treatment. Antifibrotic agents, such as nintedanib and pirfenidone, have remarkably revolutionized the treatment landscape of patients with idiopathic pulmonary fibrosis (IPF). Moreove...
Saved in:
| Main Authors: | Vito D’Agnano, Fabio Perrotta, Ramona Fomez, Valerio Maria Carrozzo, Angela Schiattarella, Stefano Sanduzzi Zamparelli, Raffaella Pagliaro, Andrea Bianco, Domenica Francesca Mariniello |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/11/1391 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Updates in the management of connective tissue disease-associated interstitial lung disease
by: Chengappa Kavadichanda, et al.
Published: (2021-01-01) -
Association of Corticosteroid Inhaler Type with Saliva Microbiome in Moderate-to-Severe Pediatric Asthma
by: Amir Hossein Alizadeh Bahmani, et al.
Published: (2025-01-01) -
Efficacy of Inhaled Corticosteroids in Patients with Bronchiectasis without Airway Hyperresponsiveness: A Pilot Study
by: Safia Ahmed, et al.
Published: (2024-11-01) -
Newer insights into the management of interstitial lung disease in systemic sclerosis
by: Robert L Mango, et al.
Published: (2017-01-01) -
Re “Inhaled Corticosteroid Particle Size and Risk of Hospitalization Rue to Exacerbations and All-Cause Mortality in Patients With Chronic Obstructive Respiratory Disease. A Nationwide Cohort Study”. Heerfordt et al [Letter]
by: Hubbard R, et al.
Published: (2025-02-01)